Lilly's weight-loss drug cuts diabetes risk by 94% in three-year trial, company says

Eli Lilly’s weight-loss drug cut the risk of developing type 2 diabetes by 94% in prediabetic adults who were overweight or obese after three years of weekly injections, the company disclosed in a statement on Tuesday. The Indianapolis, Indiana-based company said the data comes from the longest completed trial of the drug, adding that it reinforces the long-term benefits of tirzepatide — the chemical name of its Zepbound and Mounjaro treatments. Shares of the company rose 1.6% to $936.

In the trial involving 1,032 adults, patients who received weekly injections of the Lilly drug showed a 94% reduction in the risk of progression to type 2 diabetes compared to placebo up to week 176. The data comes amid concerns that patients reduce the use of weight-loss drugs over time. Reuters reported in July that only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular medications two years later.

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales SoarRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
مصدر: Forbes - 🏆 394. / 53 اقرأ أكثر »